BLAKE BOELENS: Open Payments
NPI 1407401607 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,580 in 203 payments from 21 companies in 2025. Trend: 2023 $1,603 · 2024 $2,850 · 2025 $3,580
Food & beverage: $3,572Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $471 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $409 |
| Otsuka America Pharmaceutical, Inc. | 19 | $364 |
| Janssen Pharmaceuticals, Inc | 30 | $358 |
| Teva Pharmaceuticals USA, Inc. | 18 | $350 |
| E.R. Squibb & Sons, L.L.C. | 18 | $340 |
| Vanda Pharmaceuticals Inc. | 13 | $199 |
| Supernus Pharmaceuticals, Inc. | 13 | $163 |
| Corium, LLC | 8 | $161 |
| Neurocrine BioSciences, Inc. | 6 | $151 |
Products named: VRAYLAR, CAPLYTA, REXULTI, COBENFY, AUSTEDO XR, SPRAVATO, FANAPT, Azstarys.
Industry payments across TX — which companies pay providers there.
